Publisher： Bentham Science Publishers
E-ISSN： 1873-4286|13|4|367-385
ISSN： 1381-6128
Source： Current Pharmaceutical Design, Vol.13, Iss.4, 2007-02, pp. : 367-385
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This review provides an overview of the biochemistry and activation of inflammatory caspases, and focuses on their therapeutic potential as disease targets in pathologies such as sepsis, Crohn's disease, rheumatoid arthritis, traumatic brain injury and amyotrophic lateral sclerosis (ALS). We summarize the proof-of-principal evidence obtained by studies in several corresponding experimental disease models confirming the validity of strategies targeting inflammatory caspases. We discuss the use of inflammatory caspase inhibitors, such as VX-740 (Pralnacasan) and VX-765, in clinical studies for rheumatoid arthritis and osteoarthritis. Finally, we point out recent approaches identifying novel peptidomimetic or non-peptide caspase inhibitors with suitable clinical profiles.
Related content
Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design, Vol. 13, Iss. 3, 2007-01 ,pp. :
Access to resources
Recommend
Novel Integrin-Specific Targets for Anti-Platelet Therapies
Current Pharmaceutical Design, Vol. 10, Iss. 14, 2004-05 ,pp. :